Background Psoriasis is a chronic immune-mediated inflammatory skin disease affecting
both adults and children. To better understand the efficacy-safety profile of biologics in …

The advent of biologic disease-modifying antirheumatic drugs (bDMARDs) targeting specific
cytokines or cell-cell interactions has dramatically changed the outlook of patients with …

Prescribers today find themselves in a much more difficult position than has even been the
case in the entire history of medicine. Not only do they have available to them more drugs to …

Objective Initial treatment of juvenile idiopathic arthritis (JIA) is largely based on the extent of
joint involvement, disease severity and ILAR category. The licensing of biologic therapies for …

Objective. The objectives of this study were to describe patients starting first-line biologics for
JIA, to describe characteristics over time among patients starting etanercept, and to describe …

Objectives: Juvenile idiopathic arthritis (JIA) is the most common type of inflammatory
arthritis in children. Treatment options have been expanded since the introduction of …

Abstract A recent Intercontinental Cooperative ITP Study Group (ICIS) meeting in September
2015 focused on immunomodulation across the spectrum of autoimmune conditions. It …

Biologic Response Modifiers in Pediatric Rheumatology | SpringerLink Skip to main content
Advertisement SpringerLink Account Menu Find a journal Publish with us Track your research …

Patients with rheumatoid arthritis (RA) often experience marked spontaneous improvement
during pregnancy. This classical clinical observation, documented already by Philip Hench …

Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease of the skin and joints
still poorly understood in pediatric patients. It has been reported a case report of PsA in a …